Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/035563external-prioritypatent/WO2009111337A1/en
Application filed by Novartis Ag, IrmfiledCriticalNovartis Ag
Publication of CU20100176A7publicationCriticalpatent/CU20100176A7/en
Publication of CU23948B1publicationCriticalpatent/CU23948B1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Un compuesto de la fórmula (I-A), o una sal aceptable para uso farmacéutico o un solvato aceptable para uso farmacéutico de dicho compuesto: También se dan a conocer composiciones farmacéuticas y medicamentos que los comprenden, métodos para modular un LTR, métodos para tratar una enfermedad, y una composición inmunogénica. Los compuestos son útiles como adyuvantes para mejorar la efectividad de una vacuna.A compound of the formula (IA), or a salt acceptable for pharmaceutical use or a solvate acceptable for pharmaceutical use of said compound: Pharmaceutical compositions and medicaments comprising them, methods for modulating an LTR, methods for treating a compound are also disclosed. disease, and an immunogenic composition. The compounds are useful as adjuvants to improve the effectiveness of a vaccine.
CU2010000176A2009-02-272010-09-03
COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR ACTIVITY
CU23948B1
(en)
DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
Capsule formulation comprising at least one compound of formula (i), solubilized; method of administration of the formulation; use to treat a hepatitis c virus infection.